Literature DB >> 24850790

Enhanced in vitro transcytosis of simian immunodeficiency virus mediated by vaccine-induced antibody predicts transmitted/founder strain number after rectal challenge.

Sandeep Gupta1, Poonam Pegu2, David J Venzon3, Johannes S Gach1, Zhong-Min Ma4, Gary Landucci1, Christopher J Miller5, Genoveffa Franchini2, Donald N Forthal1.   

Abstract

BACKGROUND: The time to acquisition of simian immunodeficiency virus (SIV) infection following low-dose repeated rectal challenge correlated inversely with the number of transmitted/founder strains among macaques vaccinated with ALVAC-SIV/gp120 or gp120 alone. We determined if the ability of postvaccination, prechallenge sera to enhance SIVmac251 transcytosis across epithelial cells was associated with transmitted/founder strain number.
METHODS: Transcytosis was carried out by exposing sera and SIVmac251 to the apical surface of human endometrial carcinoma (HEC-1A) cells at pH 6.0 and 12 hours later quantifying virus in fluid bathing the basolateral cell surface (maintained at pH 7.4). These conditions allow Fc neonatal receptor (FcRn)-dependent shuttling of virus across cells.
RESULTS: There was a strong correlation between the amount of virus transcytosed and number of transmitted variants (R = 0.86, P < .0001). We also found that 4 animals who remained uninfected after repeated rectal challenges had lower serum transcytosis activity than did 19 animals who subsequently became infected (P = .003). Using immunohistochemistry, we demonstrated FcRn on columnar epithelial cells facing the lumen of the macaque rectum.
CONCLUSIONS: Vaccine-induced antibody capable of enhancing transcytosis in vitro via FcRn may play a role in determining transmitted/founder strain number and infection outcomes following in vivo challenge.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Fc neonatal receptor; SIV; antibody; transcytosis; vaccine

Mesh:

Substances:

Year:  2014        PMID: 24850790      PMCID: PMC4334821          DOI: 10.1093/infdis/jiu300

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.

Authors:  Dennis R Burton; Ann J Hessell; Brandon F Keele; Per Johan Klasse; Thomas A Ketas; Brian Moldt; D Cameron Dunlop; Pascal Poignard; Lara A Doyle; Lisa Cavacini; Ronald S Veazey; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

2.  Continuous measurement by radio-telemetry of vaginal pH during human coitus.

Authors:  C A Fox; S J Meldrum; B W Watson
Journal:  J Reprod Fertil       Date:  1973-04

3.  The class I major histocompatibility complex related Fc receptor shows pH-dependent stability differences correlating with immunoglobulin binding and release.

Authors:  M Raghavan; L N Gastinel; P J Bjorkman
Journal:  Biochemistry       Date:  1993-08-24       Impact factor: 3.162

4.  Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY).

Authors:  Carolyne Onyango-Makumbi; Saad B Omer; Michael Mubiru; Lawrence H Moulton; Clemensia Nakabiito; Philippa Musoke; Francis Mmiro; Sheryl Zwerski; Hans Wigzell; Lars Falksveden; Britta Wahren; Gretchen Antelman; Mary Glenn Fowler; Laura Guay; J Brooks Jackson
Journal:  J Acquir Immune Defic Syndr       Date:  2011-12-01       Impact factor: 3.731

5.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

6.  Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals.

Authors:  Jiri Mestecky; Susan Jackson; Zina Moldoveanu; Lorie R Nesbit; Rose Kulhavy; Shirley J Prince; Steffanie Sabbaj; Mark J Mulligan; Paul A Goepfert
Journal:  AIDS Res Hum Retroviruses       Date:  2004-09       Impact factor: 2.205

7.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

Review 8.  Neonatal Fc receptor: from immunity to therapeutics.

Authors:  Timothy T Kuo; Kristi Baker; Masaru Yoshida; Shuo-Wang Qiao; Victoria G Aveson; Wayne I Lencer; Richard S Blumberg
Journal:  J Clin Immunol       Date:  2010-10-01       Impact factor: 8.317

9.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Authors:  Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Journal:  N Engl J Med       Date:  2009-10-20       Impact factor: 91.245

10.  Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1.

Authors:  Brandon F Keele; Hui Li; Gerald H Learn; Peter Hraber; Elena E Giorgi; Truman Grayson; Chuanxi Sun; Yalu Chen; Wendy W Yeh; Norman L Letvin; John R Mascola; Gary J Nabel; Barton F Haynes; Tanmoy Bhattacharya; Alan S Perelson; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  J Exp Med       Date:  2009-05-04       Impact factor: 14.307

View more
  5 in total

Review 1.  FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin.

Authors:  Michal Pyzik; Timo Rath; Wayne I Lencer; Kristi Baker; Richard S Blumberg
Journal:  J Immunol       Date:  2015-05-15       Impact factor: 5.422

Review 2.  Targeting FcRn for the modulation of antibody dynamics.

Authors:  E Sally Ward; Siva Charan Devanaboyina; Raimund J Ober
Journal:  Mol Immunol       Date:  2015-03-09       Impact factor: 4.407

3.  Antibodies and Acidic Environment Do Not Enhance HIV-1 Transcytosis.

Authors:  Oscar A Gonzalez; Manish Sagar
Journal:  J Infect Dis       Date:  2016-08-04       Impact factor: 5.226

4.  Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques.

Authors:  Sampa Santra; Georgia D Tomaras; Ranjit Warrier; Nathan I Nicely; Hua-Xin Liao; Justin Pollara; Pinghuang Liu; S Munir Alam; Ruijun Zhang; Sarah L Cocklin; Xiaoying Shen; Ryan Duffy; Shi-Mao Xia; Robert J Schutte; Charles W Pemble Iv; S Moses Dennison; Hui Li; Andrew Chao; Kora Vidnovic; Abbey Evans; Katja Klein; Amit Kumar; James Robinson; Gary Landucci; Donald N Forthal; David C Montefiori; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Merlin L Robb; Nelson L Michael; Jerome H Kim; Kelly A Soderberg; Elena E Giorgi; Lily Blair; Bette T Korber; Christiane Moog; Robin J Shattock; Norman L Letvin; Joern E Schmitz; M A Moody; Feng Gao; Guido Ferrari; George M Shaw; Barton F Haynes
Journal:  PLoS Pathog       Date:  2015-08-03       Impact factor: 6.823

5.  A Bistable Switch in Virus Dynamics Can Explain the Differences in Disease Outcome Following SIV Infections in Rhesus Macaques.

Authors:  Stanca M Ciupe; Christopher J Miller; Jonathan E Forde
Journal:  Front Microbiol       Date:  2018-06-06       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.